Skip to content
A Green Sign – Lifestyle
Author:
Pyxis Oncology
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)
November 5, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences
October 28, 2026
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 27, 2026
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
October 2, 2026
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
September 30, 2026
Pyxis Oncology Announces Proposed Public Offering
September 29, 2026
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 9, 2026
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 8, 2026
Pyxis Oncology Appoints Thomas Civik CEO & Chairman
September 8, 2026
Pyxis Oncology to Participate in Upcoming Investor Conferences
September 1, 2026
1
2
Next Page
→